Formulation Development
Absci & Almirall Announce AI Drug Discovery Partnership to Rapidly Develop Novel Treatments for Dermatological Diseases
The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases….
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals
QSAM Biosciences Inc. has signed a non-binding term sheet with Telix Pharmaceuticals (US) Inc., a subsidiary of Telix Pharmaceuticals Limited providing material terms for the acquisition of the company by….
Ocean Biomedical Announces Positive Preclinical Oncology Data for VRON-0300
Ocean Biomedical, Inc. recently announced its joint venture partner, Virion Therapeutics, LLC, recently presented highly compelling preclinical oncology data at the annual meeting of the…
Centogene, University College London & Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early Onset Dystonia & Parkinsonism
Centogene N.V. recently announced the discovery of a new form of early onset dystonia and parkinsonism in the context of neurodevelopmental abnormalities associated to the…
Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study
Artax Biopharma, Inc. recently announced the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted clinical trial authorization (CTA) to evaluate AX-158 in…
New Issue of Cayman Currents: Lipid Nanoparticles
In Cayman Currents Issue 36, Cayman Chemical showcases the ongoing discoveries and innovation advancing lipid nanoparticles (LNPs) to the forefront of modern medicine and highlights tools available to support LNP research.
Recursion Announces Data Collaboration Deal With Tempus & Updated Focus of Collaboration With Bayer
With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio….
BioXcel Therapeutics Reports Positive Overall Survival Results From Single-Arm, Open-Label Phase 2 Trial
BioXcel Therapeutics, Inc. recently announced positive overall survival (OS) data from its Phase 2 trial of BXCL701, the company's investigational oral innate immune activator, in…
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic for the Treatment of PTSD
Silo Pharma, Inc. recently announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD).…
Qualigen Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial for Treatment of Advanced or Metastatic Solid Tumors
Qualigen Therapeutics, Inc. recently announced the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective…
Yposkesi Launches AAVelocity, a Plug-and-Play AAV Platform
Yposkesi, SK pharmteco’s European clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapies (C>), recently launched AAVelocity, a plug-and-play Adeno-Associated Virus (AAV)…
Kynexis Launched to Advance Precision Therapeutics for Brain Diseases
Kynexis recently launched with €57 million in Series A financing led by Forbion, with participation from Ysios Capital and Sunstone Life Science Ventures. Kynexis will advance its lead….
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease With clonoSEQ Assay Across BeiGene’s Lymphoid Malignancy Pipeline
Adaptive Biotechnologies Corporation recently announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ assay technology across the company’s…
Imbria Reports Positive Topline Results for IND Ninerafaxstat in Patients With Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc. recently announced positive topline results from the Phase 2 IMPROVE-HCM clinical trial, evaluating ninerafaxstat, a novel cardiac mitotrope and partial fatty acid…
WEBINAR - Enabling Upstream Intensified Bioprocessing
Intensified upstream bioprocesses are being developed to increase productivity while reducing footprint, costs, and timelines for manufacturing. The higher cell densities generated by….
TriSalus Life Sciences Presents Late-Breaking Phase 1 Liver Metastasis Data; Supports Development of Innovative Immuno-oncology Approach for Liver & Pancreas Indications
TriSalus Life Sciences Inc. recently presented additional Phase 1 clinical data during the late-breaker oral presentation session at the Society of Immunotherapy for Cancer (SITC) 2023…
ProQR Strengthens Leading Intellectual Property Estate for ADAR-Mediated RNA Editing
ProQR Therapeutics N.V. recently announced it has further strengthened its leading intellectual property (IP) estate with the issuance of a new patent in the US…
Acumen Pharmaceuticals & Halozyme Enter Global Collaboration & License Agreement to Develop Subcutaneous Formulation of ACU193 With ENHANZE Technology
Acumen Pharmaceuticals, Inc. recently announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics Inc. to provide Acumen access to Halozyme’s ENHANZE drug delivery technology, based on….
Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of Oral GLP-1 Receptor Agonist for Obesity Treatment
Terns Pharmaceuticals, Inc. recently announced the first participant has been dosed in the Phase 1 clinical trial of TERN-601, the Company’s oral small-molecule glucagon-like peptide-1…
Cambrex Announces Sale of Drug Product Business Unit
Cambrex recently completed the sale of its Drug Product Business Unit to Wilmington, DE- based Noramco. Cambrex’s Drug Product business provides….
